NCT06979375

A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 40 Years – 84 Years
• Healthy volunteers: Not accepted

Summary

This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DRUG	CDR132L	Administered intravenous infusion of CDR132L once every 4 weeks for 48 weeks.
DRUG	Placebo	Administered intravenous infusion of placebo once every 4 weeks for 48 weeks.

Timeline

• Start date: 2025-06-30
• Primary completion: 2027-05-16
• Completion: 2028-01-23
• First posted: 2025-05-19
• Last updated: 2026-03-11

Locations

92 sites across 10 countries: Australia, Czechia, Germany, India, Japan, Netherlands, Poland, South Korea, Spain, United Kingdom

Regulatory

• FDA-regulated drug study